Effects of Entecavir on Serum Hepatitis B Virus-DNA, Interferon-γ, and Pregenomic RNA in Patients with Chronic Hepatitis B Virus Infection

Background: Entecavir (ETV) has been widely used in the clinical treatment of Hepatitis B Virus (HBV). However, whether ETV is helpful recovery T cell immune function remains unclear. Objectives: We aimed to assess effects on serum HBV-DNA, interferon-γ (IFN-γ), and pregenomic RNA (pgRNA) patients with infection. Methods: The data 300 HBV admitted from January 2017 2019 were retrospectively analyzed, whom 193 cases administered assigned an observation group, remaining 107 untreated (who refused treatment) a blank control group. Their liver [aspartate aminotransferase (AST) alanine (ALT)], markers [hepatitis surface antigen (HBsAg) hepatitis e (HBeAg)], IFN-γ, pgRNA, negative conversion rates HBeAg adverse reactions compared. Results: levels HBsAg, pgRNA lower group than 12, 24, 48 weeks after (P < 0.05). HBV-DNA higher those Conclusions: Antiviral therapy can inhibit replication increase rate, enhance function, reduce expression patients.